November 29, 2017 | Amid a reported shortage of the disabled viruses used for gene therapies, BlueBird Bio has purchased a 125,000-square-foot facility in Durham, North Carolina, that it will use for manufacturing the lentiviral vectors used in its treatments. Forbes